Oruka Therapeutics(NASDAQ) ORKA

Oruka Therapeutics, Inc. makes new medicines for chronic skin diseases. These treatments help people with psoriasis find long-term relief. The company uses advanced technology to improve how these medicines work.

Designing Targeted Therapies

• ORKA-001: High affinity antibody designed to block specific proteins that cause skin inflammation; engineered for dosing once or twice a year.
• ORKA-002: Extended half-life antibody targeting proteins involved in joint and skin diseases; aims for dosing every six months.
• ORKA-004: Novel antibody targeting the TNF-like ligand 1A; planned for clinical development starting in the fourth quarter of 2026.
• ORKA-003: Investigational program targeting an undisclosed pathway to expand treatments for inflammatory diseases.
• ORKA-021: Sequential combination regimen using both ORKA-001 and ORKA-002 for patients with chronic inflammation.

How Is the Pipeline Growing?

• Established research programs with Paragon Therapeutics in March 2024 to discover new antibody targets.
• Exercised exclusive options for the world-wide licenses of ORKA-001 and ORKA-002 in late 2024.
• Amended the ORKA-001 license agreement in May 2026 to include treatments for inflammatory bowel disease.
• Started a collaboration with Halozyme and made an upfront payment of $5.0 million in 2026.

Science Meets Convenience

Oruka utilizes antibody engineering and half-life extension innovations to improve efficacy and dosing schedules for standard-of-care medicines. The strategy focuses on validated biological pathways to reduce technical risk while targeting the root causes of inflammatory diseases.

The Financial Scorecard

• Net loss was $41.2 million for the three-month period ended June 30, 2026, up 68% year over year.
• Research and development expenses reached $72.4 million for the six-month period ended June 30, 2026, up 65% year over year.
• Cash, cash equivalents, and marketable securities totaled $1.1 billion as of June 30, 2026.
• Net proceeds from an underwritten public offering in April 2026 provided $658.3 million in cash.

Bottom Line

Oruka has evolved from its 2024 inception into a clinical-stage developer of specialized antibody treatments. The company focuses on creating more convenient dosing options for patients with chronic inflammatory and immunology conditions.